Allowing each member to share best practices while addressing distinct challenges facing each of the five National Centers, Quagliato perceives the struggles of implementing a National RNA Research Center as an opportunity. “This is a completely new field of biomedical and technological innovation. Therefore, we must build our network from the ground up. Our National Center aims not only to be a leader within this network but to ensure a sustainable legacy for future generations.” With the global biotech market projected to surpass $3.44 trillion by 2030, building this network focuses on the infrastructural investment of a Gene Therapy Center and RNA Production Platform that will place Italy at the helm of Europe’s post-pandemic economic growth.
Sharing strategic plans to ensure the longevity of Italy’s technological transfer investment that converts research into pharmaceutical manufacturing and production, Quagliato understands that a knowledge-based economy is key to sustainability. “The National Center continually recruits young scientists while financing a National PhD program in RNA Therapeutics and Gene Therapy as well as PharmaTech Academy to train those to operate across all phases of pharmaceutical development.”
